Dicot's CEO Elin Trampe will give her presentation at 09:00 on Monday May 2, where she will talk about the future for the company's potency drug development and the results achieved so far.

Aktiedagen Stockholm is a hybrid event arranged by Aktiespararna that both takes place physically on the Opera Terrace and is broadcasted live via YouTube. To register for the event, please go here: Registrering Aktiedagen Stockholm (https://www.lyyti.fi/reg/Aktiedagen_Stockholm_2366).

To watch the event live on Monday, click here: http://www.youtube.com/Aktiespararna

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.